Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease

医学 Evolocumab公司 心脏病学 不稳定型心绞痛 心肌梗塞 临床终点 内科学 冲程(发动机) 冠状动脉疾病 随机对照试验 载脂蛋白B 机械工程 工程类 胆固醇 载脂蛋白A1
作者
Daniel J. McClintick,Michelle L. O’Donoghue,Gaetano Maria De Ferrari,Jorge Ferreira,Xinhui Ran,KyungAh Im,J. Antonio G. López,Mary Elliott‐Davey,Bei Wang,Maria Laura Monsalvo,Dan Atar,Anthony Keech,Robert P. Giugliano,Marc S. Sabatine
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:83 (6): 652-664 被引量:23
标识
DOI:10.1016/j.jacc.2023.11.029
摘要

In FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), during a median follow-up of 2.2 years, risk reduction for major adverse cardiovascular event with evolocumab was greater in patients with multivessel disease (MVD). The FOURIER Open-Label Extension (FOURIER-OLE) provides an additional median follow-up of 5 years. The purpose of this study was to assess the long-term benefit of evolocumab in patients with and without MVD. FOURIER randomized 27,564 patients to evolocumab vs placebo; 6,635 entered FOURIER-OLE. Patients with coronary artery disease were categorized based on the presence of MVD (≥40% stenosis in ≥2 large vessels). The primary endpoint was cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; the key secondary endpoint was cardiovascular death, myocardial infarction, or stroke. Of 23,656 patients in FOURIER with coronary artery disease, 25.4% had MVD; 5,887 patients continued into FOURIER-OLE. The risk reduction with initial allocation to evolocumab tended to be greater in patients with MVD than in those without: 23% (HR: 0.77 [95% CI: 0.68-0.87]) vs 11% (HR: 0.89 [95% CI: 0.82-0.96]) for the primary and 31% (HR: 0.69 [95% CI: 0.59-0.81]) vs 15% (HR: 0.85 [95% CI: 0.77-0.94]) for the key secondary endpoints (Pinteraction = 0.062 and Pinteraction = 0.031, respectively). The magnitude of benefit tended to grow during the first several years, reaching 37% to 38% reductions in risk in patients with MVD and 23% to 28% reductions in risk in patients without MVD. Evolocumab reduced the rate of major adverse cardiovascular event in patients with and without MVD. The benefit tended to occur earlier and was larger in patients with MVD. However, the magnitude grew over time in both groups. These data support early initiation of intensive low-density lipoprotein cholesterol lowering both in patients with and without MVD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
知性的藏鸟完成签到 ,获得积分10
2秒前
华圣拿下巨蜥完成签到,获得积分10
3秒前
4秒前
5秒前
大力的可乐完成签到,获得积分10
6秒前
echowang完成签到,获得积分10
6秒前
小蘑菇的应助被zenghong采纳,获得10
8秒前
9秒前
华仔的应助被daipeng采纳,获得10
10秒前
三语掾发布了新的文献求助10
10秒前
昕昕233发布了新的文献求助10
10秒前
可爱的函函的应助被dangdindong采纳,获得10
12秒前
雪中漫步发布了新的文献求助10
13秒前
执着新竹完成签到,获得积分10
13秒前
房同学完成签到,获得积分10
13秒前
13秒前
橘子味完成签到 ,获得积分10
14秒前
赵云发布了新的文献求助10
14秒前
海边烤苞米完成签到,获得积分10
14秒前
yy32323完成签到,获得积分10
15秒前
15秒前
独特的追命完成签到,获得积分10
16秒前
Ingrid完成签到,获得积分10
17秒前
凉拌西红柿完成签到,获得积分10
18秒前
ZY完成签到 ,获得积分10
18秒前
小升初完成签到,获得积分10
19秒前
yipmyonphu的应助被独特的追命采纳,获得50
19秒前
彭于晏的应助被袁志阳采纳,获得10
19秒前
yang发布了新的文献求助10
20秒前
小巧妙梦发布了新的文献求助10
20秒前
星辰大海的应助被凑凑采纳,获得10
22秒前
三语掾完成签到,获得积分10
22秒前
无极微光的应助被xilla采纳,获得20
23秒前
Ava的应助被小升初采纳,获得10
23秒前
23秒前
xzzz完成签到 ,获得积分10
25秒前
人间慈悲的应助被黄毛虎采纳,获得10
26秒前
香蕉觅云的应助被小巧妙梦采纳,获得10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186819
求助须知:如何正确求助?哪些是违规求助? 9575195
关于积分的说明 21839872
捐赠科研通 7784526
什么是DOI,文献DOI怎么找? 3434849
关于科研通互助平台的介绍 2559266
邀请新用户注册赠送积分活动 2481716